Literature DB >> 16696311

Relationship between eukaryotic translation initiation factor 4E and malignant angiogenesis in non-Hodgkin lymphoma.

Yanxia Zhao1, Wenli Liu, Sheng Zhou, Jianfeng Zhou, Hanying Sun.   

Abstract

The relationship between angiogenesis and eukaryotic translation initiation factor 4E (EIF4E) expression level in non-Hodgkin lymphoma (NHL) was studied. Mean microvessel density (MVD) and EIF4E were detected in 52 lymph node samples paraffin sections of patients with newly diagnosed NHL by the way of immunohistochemistry. Antisense EIF4E cDNA was cloned into plasmid pcDNA3. 1 (+) and transfected into Raji cells. A series of angiogenesis related factors, including vascular endothelial growth factor (VEGF), matrix metalloproteinases 9 (MMP-9) and tissue inhibitor of metalloproteinases-2 (TIMP-2) proteins were detected by Western blot. The results showed that: (1) The Expression of EIF4E and MVD was higher in aggressive lymphomas than in indolent lymphomas (P < 0.05)and the expression of EIF4E was positively correlated with MVD in lymph node of NHL (r = 0.695, P < 0.01). (2) Antisense EIF4E eukaryocytic expression vector (pcDNA3. 1-EIF4Eas) was constructed successfully. (3) EIF4E, VEGF and MMP-9 were expressed at high levels in Raji cells as compared to normal human peripheral blood monocular cells (NHPMC), and blockage of EIF4E expression brought down the expression of VEGF and MMP-9. However, TIMP-2 was undetectable in Raji cells, although a moderate level of TIMP-2 was detected in NHPMC. It was concluded that the increased EIF4E expression was associated with aggressive property of NHL.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16696311     DOI: 10.1007/bf02896156

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  10 in total

Review 1.  The avidin-biotin complex (ABC) method and other avidin-biotin binding methods.

Authors:  G L Bratthauer
Journal:  Methods Mol Biol       Date:  1999

Review 2.  Non-Hodgkin lymphoma: an update.

Authors:  Bryan T Hennessy; Emer O Hanrahan; Peter A Daly
Journal:  Lancet Oncol       Date:  2004-06       Impact factor: 41.316

3.  Expression of the eukaryotic translation initiation factors 4E and 2alpha in non-Hodgkin's lymphomas.

Authors:  S Wang; I B Rosenwald; M J Hutzler; G A Pihan; L Savas; J J Chen; B A Woda
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

Review 4.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.

Authors:  Daniel J Hicklin; Lee M Ellis
Journal:  J Clin Oncol       Date:  2004-12-07       Impact factor: 44.544

Review 5.  Matrix metalloproteinases and their tissue inhibitors - expression, role and regulation in human malignant non-Hodgkin's lymphomas.

Authors:  A E Kossakowska; S J Urbanski; A Janowska-Wieczorek
Journal:  Leuk Lymphoma       Date:  2000-11

6.  Regulation of oct-1 gene transcription is different in lymphoid and non-lymphoid cells.

Authors:  Svetlana Zhenilo; Igor Deyev; Sergey Serov; Oleg Polanovsky
Journal:  Biochimie       Date:  2003-07       Impact factor: 4.079

7.  TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism.

Authors:  Dong-Wan Seo; Hongmei Li; Liliana Guedez; Paul T Wingfield; Tere Diaz; Rita Salloum; Bei-yang Wei; William G Stetler-Stevenson
Journal:  Cell       Date:  2003-07-25       Impact factor: 41.582

Review 8.  eIF-4E expression and its role in malignancies and metastases.

Authors:  Arrigo De Benedetti; Jeremy R Graff
Journal:  Oncogene       Date:  2004-04-19       Impact factor: 9.867

9.  Characterization of mammalian eIF4E-family members.

Authors:  Bhavesh Joshi; Amy Cameron; Rosemary Jagus
Journal:  Eur J Biochem       Date:  2004-06

10.  Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma.

Authors:  Burhan Hazar; Semra Paydas; Suzan Zorludemir; Berksoy Sahin; Ilhan Tuncer
Journal:  Leuk Lymphoma       Date:  2003-12
  10 in total
  1 in total

1.  Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin.

Authors:  Vijay Ramakrishnan; Michael Timm; Jessica L Haug; Teresa K Kimlinger; Timothy Halling; Linda E Wellik; Thomas E Witzig; S Vincent Rajkumar; Alex A Adjei; Shaji Kumar
Journal:  Am J Hematol       Date:  2011-12-21       Impact factor: 10.047

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.